SignatureDx

At SignatureDx, we are spearheading research in advanced diagnostics to develop novel methods for the early detection and treatment of complex human disease. Early diagnosis of complex human disease gives individuals the best chance for successful treatment. When care is delayed or inaccessible there is a lower quality of treatment, greater problems associated with treatment and higher costs of care. Early diagnosis improves patient outcomes by providing care at the earliest possible stage. SignatureDx is changing the paradigm of healthcare intervention by developing noninvasive methods to detect and monitor silently progressing complex human disease through our revolutionary bioanalytical platform

Signaturedx operates in the Hospitals and health care industry.

Signaturedx's revenue is 11m - 100m

Signaturedx has 11 - 50 employees.